Direct-acting Antivirals for Patients with Chronic Hepatitis C and Hepatocellular Carcinoma in Taiwan
ConclusionsThe SVR is high within BCLC B HCV-HCC patients by DAAs treatment. The risk of HCC recurrence and progression is not increased by DAAs.
Source: Journal of Microbiology, Immunology and Infection - Category: Microbiology Source Type: research
More News: Allergy & Immunology | Cancer & Oncology | Carcinoma | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | History of Medicine | Liver Cancer | Microbiology | Taiwan Health | Virology